335030-38-1

Basic information

• Product Name: TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE
• Synonyms: TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE;6-Bromo-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester
• CAS NO: 335030-38-1
• Molecular Formula: C₁₃H₁₇BrN₂O₂
• Molecular Weight: 313.19028
• Mol File: 335030-38-1.mol

Chemical Properties

• Boiling Point: 391.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.398±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.40±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE(335030-38-1)
• EPA Substance Registry System: TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE(335030-38-1)

Safety Data

• Hazardous Substances Data: 335030-38-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE is used as a building block for the synthesis of various drugs and pharmaceutical compounds. Its unique structure and properties contribute to the development of new medications with potential therapeutic benefits.
Used in Research Laboratories:
In research settings, TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE is utilized for exploring its potential biological and pharmacological activities. This helps in understanding its interactions with biological systems and identifying possible applications in drug discovery and development.
Used in Drug Discovery and Development:
Due to its high purity and quality control, TERT-BUTYL 6-BROMO-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXYLATE is suitable for applications in drug discovery and development. It aids researchers in creating novel drug candidates and optimizing existing pharmaceutical compounds for improved efficacy and safety.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1023813-80-0 6-bromo-1,2,3,4-tetrahydro-[1,8]naphthyridine 
• 129686-16-4 6-bromo-3,4-dihydro-1,8-naphthyridine-2(1H)-one 
• 335030-36-9 1-(tert-butoxycarbonyl)-1,2,3,4-tetrahydro-1,8-naphthyridine 
• 13623-87-5 1,2,3,4-tetrahydro-1,8-naphthyridine 

Downstream Products

• 676515-34-7 6-bromo-2,3-dihydro-1,8-naphthyridin-4(1H)-one 
• 335030-40-5 benzyl (E)-3-[8-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl]acrylate 

Relevant articles and documents

15-PGDH INHIBITOR

[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

ALDOSTERONE SYNTHASE INHIBITORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

FAB I INHIBITORS

Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK

Bacterial enoyl-ACP reductase (FabI) is responsible for catalyzing the final step of bacterial fatty acid biosynthesis and is an attractive target for the development of novel antibacterial agents. Previously we reported the development of FabI inhibitor 4 with narrow spectrum antimicrobial activity and in vivo efficacy against Staphylococcus aureus via intraperitoneal (ip) administration. Through iterative medicinal chemistry aided by X-ray crystal structure analysis, a new series of inhibitors has been developed with greatly increased potency against FabI-containing organisms. Several of these new inhibitors have potent antibacterial activity against multidrug resistant strains of S. aureus, and compound 30 demonstrates exceptional oral (po) in vivo efficacy in a S. aureus infection model in rats. While optimizing FabI inhibitory activity, compounds 29 and 30 were identified as having low micromolar FabK inhibitory activity, thereby increasing the antimicrobial spectrum of these compounds to include the FabK-containing pathogens Streptococcus pneumoniae and Enterococcus faecalis. The results described herein support the hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents.